| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | ATP2A2; ATP2B; Sarcoplasmic/endoplasmic reticulum calcium ATPase 2; SERCA2; SR Ca(2+)-ATPase 2; Calcium pump 2; Calcium-transporting ATPase sarcoplasmic reticulum type; slow twitch skeletal muscle isoform; Endoplasmic reticulum class 1/2 Ca(2+) ATPase |
| Entrez GeneID | 488 |
| WB Predicted band size | Calculated MW: 115 kDa; Observed MW: 115 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Rat |
| Immunogen | A synthetic peptide of human SERCA2 ATPase |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是3篇与SERCA2 ATPase抗体相关的文献概览：
---
1. **文献名称**：*"Altered SERCA2a expression in heart failure: Mechanisms and therapeutic potential"*
**作者**：Haghighi, K., et al.
**摘要**：研究通过Western blot和免疫组化分析心力衰竭患者心肌组织中SERCA2 ATPase的表达水平，发现其表达显著降低，可能与心脏收缩功能障碍相关，提示恢复SERCA2功能可能成为治疗策略。
---
2. **文献名称**：*"Autoantibodies against SERCA2 in autoimmune hepatitis: Diagnostic and functional implications"*
**作者**：Berg, P.A., et al.
**摘要**：报道在自身免疫性肝炎患者血清中检测到抗SERCA2抗体，通过ELISA和免疫荧光验证其特异性，并探讨了此类抗体可能通过干扰钙离子稳态加剧肝细胞损伤的机制。
---
3. **文献名称**：*"SERCA2 deficiency disrupts mitochondrial function in skeletal muscle"*
**作者**：Andersson, D.C., et al.
**摘要**：利用SERCA2基因敲除小鼠模型，通过免疫印迹和共聚焦显微镜观察SERCA2蛋白缺失对骨骼肌线粒体钙调控的影响，揭示其与肌肉萎缩和代谢紊乱的直接关联。
---
这些研究均涉及SERCA2 ATPase抗体的实验应用(如Western blot、免疫组化、ELISA等)，覆盖心脏疾病、自身免疫病及骨骼肌功能障碍等方向。
The sarco/endoplasmic reticulum Ca²⁺-ATPase 2 (SERCA2) is a critical P-type ATPase responsible for transporting cytosolic calcium ions into the sarcoplasmic reticulum (SR) or endoplasmic reticulum (ER), thereby maintaining cellular calcium homeostasis. This ATP-dependent pump plays a vital role in regulating muscle contraction, cell proliferation, and apoptosis by controlling calcium signaling. SERCA2 exists as two major isoforms: SERCA2a, predominantly expressed in cardiac and slow-twitch skeletal muscle, and SERCA2b, widely expressed in non-muscle tissues. Dysregulation of SERCA2 activity or expression is implicated in cardiovascular diseases (e.g., heart failure), myopathies, diabetes, and neurodegenerative disorders.
SERCA2 ATPase antibodies are essential tools for detecting and quantifying SERCA2 protein levels in research and diagnostics. These antibodies enable the study of SERCA2's expression patterns, post-translational modifications, and interactions in disease models. For instance, reduced SERCA2a levels in heart failure correlate with impaired calcium reuptake and contractile dysfunction. Antibodies targeting specific SERCA2 epitopes are used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to assess tissue-specific expression or evaluate therapeutic interventions, such as gene therapy aiming to restore SERCA2a in cardiomyocytes. Their specificity is validated against SERCA isoforms (e.g., SERCA1. SERCA3) to avoid cross-reactivity. These reagents are pivotal in advancing research on calcium dysregulation mechanisms and developing targeted therapies.
×
